<?xml version="1.0"?>

<document>
	<title>Animal model for cystic fibrosis: pulmonary clearance of
   Staphylococcus aureus in mice treated with reserpine.</title>

	<author>Sordelli-D-O.</author>
	<author>Cassino-R-J.</author>
	<author>Pivetta-O-H.</author>

	<source>Life-Sci. 1979 May 21. 24(21). P 2003-10.</source>

	<abstract>Since it has been demonstrated that chronic administration of
   reserpine to rats produces CF-like alterations, we have studied the
   lung resistance to bacterial infections in animals treated with
   reserpine.  Mice of the BALB/c inbred strain were injected
   subcutaneously with different doses of reserpine for 7 days; after,
   they were submitted to an infective aerosol containing
   Staphylococcus aureus in a nebulization chamber.  With each pair of
   exposed animals, an individual value of the uncleared bacteria ratio
   (UBR) at 4 hours was obtained.  Reserpinized animals showed a
   significant increase in UBR values when compared to control mice (p
   &lt; 0.05 and p &lt; 0.01 depending on the doses), suggesting an
   impairment of the lung antibacterial defenses.  Although
   pharmacological doses of reserpine produce catecholamine depletion,
   we can not conclude that this action upon the nervous system is the
   only cause of the CF-like response we detected.  In conclusion, the
   observed UBR decrease lends support to the concept of a reserpine-
   induced CF animal model.</abstract>

	<majorsubject>CYSTIC-FIBROSIS: pp</majorsubject>
	<majorsubject>LUNG: mi</majorsubject>
	<majorsubject>RESERPINE: pd</majorsubject>
	<majorsubject>STAPHYLOCOCCUS-AUREUS</majorsubject>

	<minorsubject>ANIMAL</minorsubject>
	<minorsubject>DISEASE-MODELS-ANIMAL</minorsubject>
	<minorsubject>FEMALE</minorsubject>
	<minorsubject>LUNG: de</minorsubject>
	<minorsubject>MALE</minorsubject>
	<minorsubject>MICE</minorsubject>
	<minorsubject>MICE-INBRED-BALB-C</minorsubject>

	<reference>001   DI SANTAGNESE PA      N ENGL J MED                   295   481 976</reference>
	<reference>002   WOOD RE               AM REV RESPIR DIS              113   833 976</reference>
	<reference>003   OPPENHEIMER EH        COMPAR PATHOL BULL             111     3 971</reference>
	<reference>004   MARTINEZ JR           PEDIATR RES                      9   463 975</reference>
	<reference>005   PIVETTA OH            PEDIATR RES                     11  1133 977</reference>
	<reference>006   THOMPSON FE           PEDIATR RES                     10   632 976</reference>
	<reference>007   SNEDECOR GW           STATISTICAL METHODS                      967</reference>
	<reference>008   FINNEY DJ             PROBIT ANALYSIS                          971</reference>
	<reference>009   TAYLOR PW JR          J PHARMACOL EXP THER           156   483 967</reference>
	<reference>010   GREEN GM              J CLIN INVEST                   43   769 964</reference>
	<reference>011   LEE JA                FED PROC                        35   262 976</reference>
	<reference>012   STITZEL RE            PHARMACOL REV                   28   179 977</reference>
	<reference>013   MARTINEZ JR           PROC WORKSHOP ON MODEL SYS CF            978</reference>
	<reference>014   MENOM AL              J PHARM PHARMACOL               28   827 976</reference>
	<reference>015   GREEN GM              BR J EXP PATHOL                 46   360 965</reference>

	<citation>1   HAZLETT D             PEDIATR RES                     20  1236 986</citation>

</document>
